By Therapeutic Area

Cardiovascular & Endocarditis-Related HAI Market Analysis

Cross-industry research covering Cardiovascular & Endocarditis-Related HAI across 1 market reportspanning Pharmaceuticals.

1 Reports

1 Industries

Reports Covering Cardiovascular & Endocarditis-Related HAI

Hospital Acquired Infection Control Market to Reach USD 41.6B by 2033 at 6.4% CAGR

Pharmaceuticals·Market: USD 25.3 Billion (2025)·CAGR: 6.4%

The 2023 ESC Guidelines for endocarditis management (openalex:W4386153816) mandate extended IV antibiotic courses, driving sustained inpatient antimicrobial spend estimated at USD 780M annually in Europe and North America (Claritas model). Post-cardiac surgery HAI prophylaxis, including alpha-ketoglutarate strategies under evaluation in CABG patients (nct:NCT07031128), adds a nascent metabolic-adjunct dimension.

Market Share

6.0%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments